The relationship between DNA methylation depending on genetic variations in the PON1 gene promoter and between bleeding or MACE occurrence during dual antiplatelet therapy was also evaluated in patients with CAD, who underwent PCI. The gene discussed is PON1; the disease is coronary artery disorder.